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Privacy is dead
If the cost of sports cars had fallen at the same rate as genome sequencing, 
we could all be driving around in Ferraris that cost 40 cents, reported a 
scientist from Stanford Medical School recently. But in the rush for the 
1,000-dollar (or euro) genome, are we forgetting the many other costs and 
concerns that come with ‘more data for less money’? Is technology moving 
faster than our ability to make sense of it? 
Using genome based information and technologies for the benefit of public 
health is dependent on vast biobanks of data. And those data need to be 
linkable. From what we know already, it will not be our DNA or genes 
alone that will determine aspects of our health; we need to incorporate 
factors related to our environment and lifestyles. We need big data. 
The privacy (or not) of those data is the focus of this issue’s Special Report. 
How, when, and with whom, should genomic data be shared? Once whole 
genome information is included, it is generally believed that medical data 
cannot be effectively anonymised. Privacy is dead. Yet the use of biobanks 
and the genetic links they could reveal (even if so far, they have proved 
elusive) is the structure behind the future public health vision of predictive, 
preventative and personalised healthcare. 
The chaos surrounding the UK Government’s attempt to roll out the 
care.data project linking local doctor and hospital records (against a 
vigorous ‘opt-out’ campaign) shows just what happens when policy makers 
underestimate the need for public engagement. As the PACTIA Future 
Panel on public health genomics noted: “The extent to which genomics 
data are collected, stored, shared, and for what purposes, is first of all 





Building bridges in Cophenhagen
‘Science building bridges’ is the theme 
of EuroScience Open Forum 2014 
(ESOF2014) in June when Copenhagen 
will welcome 2,300 visitors from 40 
countries including superstars from 
the world of  science.  The exhibition, 
conference, ambitious Science in the 
City outreach festival, and the special 
area for students – ESOF Academy 




Euroscience Open Forum (ESOF) 
2014, Copenhagen, Denmark, 21-26 
June 2014
Science and wonder
The 2014 World Science Festival 
comes to Amsterdam in SeptemberIn 
partnership with the city of 
Amsterdam and other prestigious 
local partner organizations. WSF 
presents compelling educational 
and entertaining science events that 
capture the excitement and wonder of 
science, as well as the great potential 
that science offers for addressing the 




World Science Festival Amsterdam 
Amsterdam, Netherlands, 6-7 
September 2014  
Better Technologies with no 
Regrets?
The Society for the Study of 
Nanoscience and Emerging 
Technologies (S.NET) holds its sixth 
annual meeting at the Karlsruhe 
Institute of Technology in Germany 
in September. It will address 
nanoscale science and engineering, 
biotechnology, synthetic biology, 
neurotechnologies, cognitive science 
and geo-engineering from responsible 
research to governance and politics. 
www.itas.kit.edu/snet2014 
 
S.NET 6th Annual Meeting  
Karlsruhe Institute of Technology, 




20 years at ITA
Public participation is a crucial source of knowledge according to 
Austria's technology assessment institute.
 
Two decades of raising awareness 
The ITA, Austria’s only dedicated TA institution, celebrates its 
20th anniversary in June with a kick-off event and conference at the 
Austrian Academy of Sciences exploring the connection between 
responsible research and TA. Two decades of research has seen the ITA’s 
involvement in a wide range of projects dealing with the regulation of 
nanotechnologies, food safety, synthetic biology and recently co-hosting 
a large scale citizen’s forum on surveillance technologies as part of the 
EU initiative SurPRISE. It is constantly strengthening its relationship 
to parliament and international TA networks such as EPTA and NTA. 
“Building a community is very important to us”, stresses director 
Michael Nentwich. “Technology assessment is not something that is 
done just for a small group of experts. We want to offer up our research 
results to decision makers in a way that gives them more 
control over their respective fields, and we strongly believe that public 
participation is a crucial source of knowledge in this process. I am 
really looking forward to celebrate our 20th anniversary with so many 
colleagues who helped raise awareness for TA and bring it to a whole 
new level in Europe”. Guest of honour is Professor Renate Mayntz, 
the German doyenne of sociology, who was recently given a lifetime 
achievement award by the German Sociological Association. 
Luma.Launisch, winners of the 
city of Vienna’s Kreativ award, 
will contribute an audio-
visual installation and a visual 
symphony designed especially 
for the ITA.
 
The ITA – Celebrating 20 Years + 
NTA6-TA14, Vienna,2-4 June 2014 
www.oeaw.ac.at/ita
Europe’s only TA PhD 
programme
Enrolment open until June
The TA PhD programme at the 
Universidade Nova de Lisboa 
(Portugal) Faculty of Sciences and 
Technology (FCT-UNL) is the 
only one of its kind in Europe. It is 
structured in collaboration with the 
Karlsruhe Institute of Technology 
with support from universities in 
Frankfurt, Duisburg-Essen, Liège, 
Sofia, Vilnius, and other experts 
from TA institutes (mostly from 
the PACITA network). The PhD 
programme develops studies and 
knowledge in emergent knowledge 
fields including e-mobility, brain-
computer interfaces, health TA, 
nanotechnology, energy storage, 
cloud computing, and railway 
and road transport. The duration 
of the programme is typically 4 
years. Most students are actively 
involved in the national TA 
network, and take part in several 
PACITA activities (e.g. practitioner 
workshops, summer schools, TA 
conferences). Students from other 
countries such as Brazil, Austria, 
Turkey, Bulgaria and Lithuania 
have also taken part. The courses 
are in Portuguese and English. 
The enrolment period for the 
2014 winter semester (starting in 








Nanotechnology is a megatrend which will match 
or surpass the digital revolution’s effect of science on 
the economy. But there are funding gaps. That’s the 
view of participants in a strategic forum held by the 
US Government Accountability Office (GAO).
 
GAO report on nanomanufacturing
What are future nanotech developments? How 
big will they be? Are the US R&D investments in 
nanomanufacturing sufficient? What effect will 
nanotechnology have on the environment, our 
health and safety? Those were the questions nano 
experts addressed in a strategic forum held by the 
US Government Accountability Office (GAO). 
The report, Nanomanufacturing: Emergence 
and Implications for U.S. Competitiveness, the 
Environment and Human Health, is the result. 
More intense competition 
Members of the forum anticipate further scientific 
breakthroughs that will fuel new engineering 
developments and more intense international 
competition. Although limited data on international 
investments made comparisons difficult, participants 
see the US as likely to lead in nanotechnology 
research and development (R&D). Challenges to 
US competitiveness in nanomanufacturing include 
inadequate US participation and leadership in 
international standard setting; the lack of a national 
vision for a US nanomanufacturing capability; 
and the actions of competitor nations. According 
to a participant, some ‘were playing by new rules’. 
There are funding or investment gaps in the United 
States which could hamper innovators’ attempts to 
transition nanotechnology from R&D to full-scale 
manufacturing.
The Valley of Death and the Missing Middle 
The significant development costs for 
nanotechnology projects has led to funding scenarios 
which participants described as the ‘valley of death’ 
and the ‘missing middle’: the research and funding 
gap that can occur after the initial development of in 
a new technology and its subsequent development; 
or the lack of funding related to maturing 
manufacturing innovation. “High costs can act as an 
effective barrier to entry for small and medium-sized 
companies that have innovations in technology but 
lack the resources needed to carry their innovations 
all the way to commercialization and full-scale 
production.” 
News 
A participant suggests that this is not the case 
in China, Russia and the European Union. 
“Government investments in establishing 
technology platforms, technology transfer, and 
commercialization are higher in other countries than 
in the United States.”
The Forum suggests three approaches to address 
these challenges: strengthen US innovation by 
updating current innovation-related policies 
and programs; promote US innovation in 
manufacturing in public-private partnerships; and 
design a strategy for attaining a holistic vision for 
U.S. nanomanufacturing. Significant research is 
needed to understand the risks associated with 
nanomaterials and multiple participants advocated 
a collaborative effort, in which nanotechnology 
stakeholders develop standards for measurement 
and nomenclature, to help assess and address 
environmental health and safety (EHS) risks. 
Read More? 
Nanomanufacturing Emergence and Implications for U.S. 
Competitiveness, the Environment, and Human Health. 
Highlights of a forum Convened by the Comptroller 
General of the United States GAO-14-181SP Jan 2014. 
www.gao.gov/products/GAO-14-181SP.
About the GAO 
The U.S. Government Accountability Office (GAO) is 
an independent, nonpartisan agency that works for 
Congress. Often called the ‘congressional watchdog,’ 
GAO investigates how the federal government spends 
taxpayer dollars. The head of GAO, the Comptroller 
General of the United States, is appointed to a 15-year 
term by the President from a slate of candidates Congress 
proposes.
A holisitic vision is 
needed for US nano 
manufacturing according 





















Last year, Yaniv Erlich, a 34-year-old ex-security 
specialist turned computational biologist, rocked 
the genomics world by showing that it is possible 
to discover the identities of anonymous people 
who participate in genetic research studies. He 
did so by cross-referencing their genetic data with 
surnames found on the internet. 
Earlier studies, such as by Nils Homer in 2008, 
had already shown that people listed in anonymous 
genetic databases could be unmasked by matching 
their data to a sample of their DNA. All that was 
needed was some DNA obtained from a discarded 
paper coffee cup, and open source Genome Wide 
Association Studies (GWAS) datasets to associate 
particular individuals with specific diseases.
But Erlich, named ‘The Genome Hacker’ by science 
magazine Nature showed something else: that 
it is possible to identify people by linking their 
genetic data to freely available information. All 
it took was an internet connection and a smart 
piece of software - an algorithm called lobSTR, 
Special Report – Public Health Genomics
Sharing DNA in a big data world 
Private health?   
Text: 
Pascal Messer 
Photos courtesy of the 
Portuguese Parliament 
‘With the current speed of genomic 
advances…everybody, be it on a 
personal level, or at a European 
decision making level, needs to start 
forming an opinion on it.’ 
The success of Public Health Genomics  - using genome-based 
information and technologies for the benefit of public health - is 
dependent on access to vast biobanks of data. But how, when and with 
whom should our DNA and medical data be shared? How can we protect 
patients’ genomic data without stifling research?
Special Report
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designed by undergrad student Gymrek - to expose 
vulnerabilities in databases that hold sensitive 
information on thousands of people around the 
world. 
Privacy is dead
‘In the genomics era, privacy is dead’. This phrase 
was heard several times at the PACITA Policy 
Hearing on Public Health Genomics that took 
place in January in Lisbon. It did not raise many 
eyebrows, though. The hearing, which aimed 
to address pressing political issues related to 
genomic technologies, brought together an eclectic 
gathering of international geneticists, technology 
assessment practitioners, public health experts, 
parliamentarians, jurists, patient representatives 
and policymakers. The PACITA ambitions 
were high: it wanted to bring stakeholders and 
politicians together to set a policy agenda for 
the ‘responsible introduction of Public Health 
Genomics’. 
Perhaps there was simply too much to discuss, 
that day in Lisbon, and too many aspects of public 
health genomics to deal with. When politicians 
were asked at the end of the day, what they would 
take home as a pressing political issue, a member 
of the European Parliament said: “With the 
runaway costs of spending on public health, and 
genomics being a possible tool for that, it is an 
interesting topic. But when I get home, nobody is 
going to care about what I learned today, because 
they are only interested in day-to-day politics.” 
Another one answered: “Well, I guess I’ve got more 
questions now than I had before I came. I had a 
naïve hope that the experts would tell me what 
to do. I have got a kind of picture of where we’re 
going, but no clue of how we will get there.” 
Compelling reasons
There are many compelling reasons for politicians 
to meet with geneticists and other stakeholders, 
though. In less than a decade, whole genome 
sequencing (WGS) has moved from a revolutionary 
moon-landing-style science project to a worldwide 
seedbed of entrepreneurial activity. The price 
of DNA sequencing technologies is dropping so 
rapidly that experts believe our children will have 
their full genomes read as part of their medical 
record, and as part of a completely new model 
of personalised public healthcare. But alongside 
the anticipated public health benefits, come lots 
The ultimate identifier 
Human DNA sequence is often called the ‘ultimate 
identifier’. Our DNA is unique (except for identical twins). It 
can be used to predict a variety of medical conditions and 
traits. Think: hair, skin and eye colour, facial features, height, 
and, allegedly, even smoking habits. Recent studies suggest 
that our genes steer our voting and economic behaviour, 
and our ability to stick to our spouses in marriage. 
Lisbon, 18 January 
2014: The PACITA 
policy hearing on Public 
Health Genomics in the 
Portugese parliament 
brought together 




of ethical and legal issues. How, when and with 
whom should we share our DNA and medical 
data? Policymakers and researchers will need to 
tread very carefully in crafting policies that protect 
patients’ genome data without stifling research. 
DNA and privacy
The privacy and confidentiality concerns about whole 
genome data go a lot further than a simple decision 
about whether to have your genome sequenced for 
private medical reasons, and if so, whether these 
data should become part of your medical record. 
Sequencing a whole genome is still primarily done 
for research purposes, as scientists piece together 
which genetic mutations play a role in diseases. This 
often happens in large-scale (cohort) studies, some 
of them open source, which compare the DNA of 
two large groups of individuals, one healthy control 
group and one case group affected by a disease. 
Whole genome research involves the collection and 
storage of a biological sample, the sequencing of 
the genome, data analysis, and, more and more 
frequently, the release and exchange of these data 
in scientific databases to facilitate research. But 
these processes are complicated by a number of 
other issues: the quantity of genetic information 
that is made available to commercial parties and 
public private partnerships, the commercialization 
of research results, the combination of genetic data 
and electronic health files, out of date consent 
procedures, data anonymisation capabilities and 
many other privacy concerns. 
Monetarisation of medical data
The day after the PACITA hearing in Lisbon, some 
of the urgent political issues surrounding Public 
Health Genomics – and it’s dependence on big 
data – hit the headlines, as British newspaper The 
Guardian reported on the potential commercial 
availability of medical records in the new care.data 
service proposed by the National Health Service 
(NHS England). The scheme aims to ‘join up’ 
doctors’ and hospital medical records of millions 
of citizens in order to improve medical services. 
To help diagnose drug side effects, for example, 
and evaluate the performance of hospital surgical 
units and procedures, by tracking their impact 
on patients. The newly established data services 
provider, the Health and Social Care Information 
Service (HSCIS) will have the legal right to extract 
data from GP Practices – a process that was meant 
to begin this month (see below). The extracted 
information is anonymised to some extent - 
stripped of the patient’s name - but the records 
do contain (parts of) a person's NHS number, 
date of birth, postcode, ethnicity and gender. The 
care.data plan is part of a huge governmental 
investment scheme that aims to boost the British 
life sciences industry. Collecting, storing, and 
analysing ‘national healthcare, public health and 
social care data, including personal data’, should 
make the UK, the ‘leader in the race for better 
tests, better drugs and above all, more personalised 
care to save lives’, as Jeremy Hunt, UK Secretary of 
State for Health stated.
What’s gone wrong with care.data?
Widespread unease expressed by both the medical 
profession and patient groups have led to the roll out 
of the scheme being put on hold for six months.  
Care.data has run into a volley of privacy 
accusations. Would police and government bodies 
have the right to access people's medical data? Even 
when medical data has been anonymised, how easy 
is it piece together evidence to identify an individual 
and thereby discover information about them from 
their health record? It doesn’t help that the NHS has 
form in the sloppy care of medical records. Right 
wing newspaper The Daily Mail, reported that in 
2012, the NHS ‘lost track of 1.8 million confidential 
patient records in a single year’. ‘Sensitive’ paper 
records have been dumped in public bins and landfill 
sites. Computers containing medical records were 
found for sale on ebay, the newspaper reported. The 
opt-out procedure, rather than an opt-in scheme 
did not pass muster either. Patients who want to 
opt out of care.data need to arrange it with their 
GP. And it is not clear what data will be blocked. 
According to some experts, it is inevitable that the 
medical data of all Britons – whether with consent or 
not - will be sucked into the database. What seems 
universally agreed is that patient awareness – of the 
benefits as well as privacy implications – is at very 
low levels. Organisations such as the British Medical 
Association have therefore welcomed the delay. 
‘Care.data is in chaos’, wrote Ben Goldacre in The 
Guardian in Feburary. “HSCIC needs to regain trust, 
by releasing all documentation on all past releases, 
urgently. Care.data needs to work: in medicine, data 
saves lives.”
DNA and medical records
Selling sensitive medical data of citizens is one thing 
that would need careful democratic deliberation. But 
when DNA is to become part of electronic health 
records - as envisioned by Personal Health Genomics 
enthusiasts - many believe that public awareness and 
political scrutiny becomes even more important. In 
the UK, according to British NGO Genewatch, it is 
indeed the ultimate aim of the British Government to 
have the genomes of all 60 million Britons sequenced 
and attached to their electronic health records. In 
July 2013, the Department of Health announced 
the launch of Genomics England and the start of 
the 100k Genomes Project. Over the next five years, 
the personal DNA of up to 100,000 NHS patients 
will be sequenced. A spokesperson for this project 
said: “This unrivalled knowledge will help doctors’ 
understanding, leading to better and earlier diagnosis 
and personalised care. Based on expert scientific 
advice, we will start by tackling cancer, rare diseases 
and infectious diseases.” UK prime minister David 
‘Care.data needs to work: in 
medicine, data saves lives’
Special Report
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Cameron stated: “It is crucial that we continue to 
push the boundaries and this new plan will mean we 
are the first country in the world to use DNA codes 
in the mainstream of the health service. By unlocking 
the power of DNA data, the NHS will lead the global 
race for better tests, better drugs and above all better 
care.” 
For researchers, the linking of genomic data to 
data from medical health records is crucial. To 
fully understand what triggers disease or not, DNA 
has to be linked to other factors, such as health 
data and lifestyle and social and environmental 
factors. To figure out what exactly causes lung 
cancer, one would not only study genes and 
smoking habits but also demographics: postal 
codes, to see if air pollution plays a part in 
developing disease. 
The collection of bio specimens, like samples 
of urine, blood, tissue, cells, DNA, RNA, and 
protein and other data, for research purposes is 
nothing new. It has a long history in educational 
and medical systems, remaining largely 
uncontroversial, hidden away in the seclusion of 
pathology institutes. But with recent genomics 
advances, big data claims and booms in IT 
technology, the potential of opening up existing 
collections of bio specimen in biobanks, or 
starting new collections, has become a feverish 
pursuit. All around the globe, governments and 
companies are rushing into ambitious projects 
to find out how genome technology can best be 
used in a medical context. Huge data sets, with 
the DNA of hundreds of thousands of people, are 
needed to uncover genetic links (that have so far 
proved elusive), but that are needed to address the 
promise of personal medicine. As a report by the 
European Commission states: “The development 
of biobank infrastructure and the use of this as 
a basis for personalised medicine has become a 
central strategic goal in the fields of European 
biotechnology, genomics and international 
politics.” 
World leaders
According to the European Commission, EU 
member states already are ‘world leaders in 
the development of biobanking infrastructure 
to support research, making huge investments 
each year to support such initiatives’. To give 
some examples: over the past few years, the UK 
Biobank has recruited 500,000 people aged 
between 40-69 years to provide blood, urine and 
saliva samples for future analysis. They provided 
detailed information about themselves and agreed 
to have their health followed for a long time. The 
Faroe Islands, an autonomous country within 
the Kingdom of Denmark, is offering genomic 
sequencing to all of the citizens of this archipelago, 
to understand the particular genetic diseases 
prevalent in this isolated population. 
The same is happening elsewhere. In November 
2011, the Beijing Genomics Institute launched 
the Million Human Genomes Project, to decode 
the genomes of over 1 million people for projects 
based in China and abroad. In the US, the 
US Department of Veterans Affairs (VA) has 
been collecting the medical records and blood 
samples of a million U.S. veterans since 2012. 
Dr. Joel Kupersmith, the VA's chief research 
and development officer told US newspaper The 
Baltimore Sun that researchers: “have long seen 
the potential at the VA because the system has 8 
million enrollees of various ages and ethnicities 
Personalised medicine? 
DNA is the basis of all life on earth, including human 
life. The methodologies for reading the DNA sequence 
- to unravel the code of life - are currently undergoing 
revolutions in both speed and cost. The first complete 
sequence of the human genome, completed in 2003, took 
more than a decade to complete, at a price of roughly 3 
billion euros. These days, it takes roughly 2-4 weeks to read 
the full DNA of a human at a cost of 2,000-5,000 euros. 
Within the next five years, it is expected to take just one day, 
for less than 500 euros. According to genomics believers, 
the two major consequences will be: that medicine will 
become genome-based, personalised: products, tests and 
supplements tailor made to our unique building plan. 
The second consequence will be an increase in ‘predictive’ 
diagnosis: our DNA could be used to reveal the strong and 
weak points of our body, our talents and any hidden risks 
including genetic diseases. Although we are still in the 
early days of understanding the genetic code, progress is 
being made regarding disease-associated DNA variants. 
Genome-based research is already enabling medical 
researchers to develop more effective diagnostic tools, 
to better understand the health needs of people based 
on their individual genetic make-ups, and to design new 
treatments for disease. Most new drugs based on genome-
based research are estimated to be at least 10 to 15 years 
away. It is very difficult to predict how much of our lives will 
by driven by our DNA in the end. From what we know now, 
both disease and health stem from a combination of our 
DNA, our environment and our lifestyle. 
‘The development of biobank 
infrastructure and the use of 
this as a basis for personalised 
medicine has become a central 
strategic goal in the fields 
of European biotechnology, 




with most every kind of age, health, and service-
related disorder. All have an electronic medical 
record stretching up to 15 years.” 
Reluctant donors 
A big problem with biobanking, though, is that 
in Europe, hardly anybody knows about it. A 
2010 Euro barometer survey on life sciences 
and biotechnology, conducted in 32 European 
countries, showed that more than two thirds of all 
Europeans said they have never heard of biobanks. 
When there were told, many European citizens 
appeared to be reluctant to become donors or 
participants in cohort studies. According to the 
survey,  concerns about privacy and confidentiality 
are the first things that spring to mind. Although 
many people these days seem willing to post their 
intimate information on social networks, medical 
data are still considered as being highly sensitive. 
Sharing medical information, illnesses and 
ailments, is tightly connected to the doctor-patient 
relationship, and the fundamental right of medical 
confidentiality. People also fear that the long term 
storage of their data could be turned against them, 
through the violation of their privacy rights or 
through discrimination by insurers or employers. 
Consent
One of the most controversial aspects of 
biobanking is the current use of ‘broad consent’, 
for those enrolling in a biobank rather than 
seeking ‘informed consent’ from participants. 
For practical reasons, according to the EU 
Commission, ‘broad consent is now the norm for 
biobank recruitment’. Participants are asked to 
consent once to the broad use of their samples 
and data, rather than to specific, new or future 
research projects. This is not simply because 
researchers are reluctant to add extra barriers to 
their work and would prefer to spend time on their 
research rather than wrestle with added layers 
of bureaucracy. Sometimes asking for renewed 
consent has no benefit for patients; sometimes it 
is simply impossible. This is a problem for studies 
that use archived samples, for example. These 
samples were often collected using a consent 
process (if a consent process was used at all) that 
did not anticipate the potential identifiability of 
genomic data. But the use of broad consent for 
biobanking creates tensions because “data may 
be shared with large numbers of researchers, 
including commercial companies, both nationally 
and internationally, for purposes which may 
be unclear when the data sets are collected.” 
according to the PACITA Expert report. A recent 
international study involving European wide 
focus groups was very clear on consent. Despite 
the perceived (research) need for broad consent, a 
large majority of Europeans (67%) would choose 
narrow consent and only 24% broad consent. 
As the authors observed: “It was a minority of 
people who thought it appropriate not to be asked 
for permission to have their details and samples 
entered in a biobank.”
Lacking rules
Research and biobanking communities have a 
long tradition in successfully guarding privacy 
and medical confidentiality and are scrambling 
to maintain this within a big data environment. 
They are setting up research ethics boards and 
data access committees, reviewing and publishing 
codes of conduct and governance mechanisms, 
and developing encryption and key management 
systems to restrict data access. But at present, 
genome researchers simply have no model to 
follow for protecting the privacy of genetic donors. 
As one geneticist quietly joked at the PACITA 
hearing: “China has by far the biggest genomics 
industry worldwide, and we exchange lots of data 
with the Chinese, but do you think they care much 
for privacy or human rights?”  
The problem is that there is no clarity on consent 
procedures, and no consistent and coherent rules 
in the areas of privacy, data protection, the use 
of human tissue in research, and the exchange 
of these data across national borders. There are 
big differences between the implementation and 
enforcement of legal provisions, even among the 
EU countries that have signed the Data Protection 
Directive. Data protection rules are currently being 
revised by the new Data Protection Regulation, 
which is expected later this summer. However, 
biobank managers have en masse expressed 
concern that too strict a regulatory framework 
for human biobanks within Europe will create 
uncertainty and inhibits the building of a biobank 
infrastructure.
Heightened tensions
The current regulatory vacuum leads to heightened 
tensions between the individuals’ need for privacy 
and confidentiality, and the needs of researchers 
and biobankers for their pursuit of a societal 
benefit. Is asking for ‘broad consent’ in a genomic 
era ethically appropriate, and if it is, how should 
it be handled? Too strict a focus on privacy and 
confidentiality is likely to hamper research. Many 
researchers feel that because of privacy rules, a lot 
of what is learned from genetic studies is neither 
published nor shared, and is therefore lost. David 
Altshuler, deputy director of the Broad Institute 
of MIT and Harvard, recently said in Scientific 
‘China has by far the biggest 
genomics industry worldwide, and 
we exchange lots of data with the 
Chinese, but do you think they 




American: “There are literally millions of people 
who participate in medical research, and probably 
over a million people whose genomes have been 
characterized in some way or another, where the 
data is not freely available precisely because of 
privacy concerns.”
Biobanks are often paid for with taxpayers 
money and strongly depend on public support 
– if only  for donations of samples and data. As 
the EU Commission report notes how these are 
controversial undertakings: “Not all biobank 
projects are warmly reviewed by all groups 
in society.” US President Obama’s Bioethicist 
Commission reported in 2013: “Without public 
trust, people may not be as willing to allow 
scientists to study their genetic information.” 
Securing acceptance and public trust, by creating 
awareness and transparency, and by finding 
solutions to balance a range of competing interests, 
is crucial to a successful translation of genome-
based technology from research to the clinic. 
Weighing competing interests, setting boundaries, 
and finding a balance between protecting 
individuals’ privacy and the greater good, is what 
politicians should do. 
Awareness
The need for policy makers to address these public 
awareness issues more rigorously was emphasized 
at the PACITA hearing. Stressing the importance 
of informed citizens, awareness and education, 
Klaas Dolsma from the Dutch Erfocentrum, the 
national information centre on genomics and 
hereditary diseases, said: “With the current 
speed of genomic advances, it is for sure that at 
some time in our lives, each and every one of us 
will have to make decisions about genetic testing 
and hereditary disease. So everybody, be it on a 
personal level, or at a European decision making 
level, needs to start forming an opinion on it.” 
Maria De Belém Roseira 
(Portugal), Yvonne Gilli 
(Switzerland), Vittorio 
Prodi (Italy), Jens Henrik 
Thulesen Dahl (Denmark). 
‘There are probably over a million 
people whose genomes have been 
characterized in some way or 
another, where the data is not 
freely available precisely because 
of privacy concerns.’
Read more? 
The Genome Hacker – Erika Check Hayden, Nature (2013)
Think tank on Identifiability of Biospecimens and -Omic Data, 
US Department of Health and Human Services (2012) 
Biobanks for Europe - A Challenge for Governance,  European 
Commission (2012)
Privacy and Progress in Whole Genome Sequencing, US 
Presidential Commission for the Study of Bioethical Issues 
(2012)
Whole Genome Sequencing: Innovation Dream or Privacy 
Nightmare? E. De Cristofaro (2012)
Data storage and DNA banking for biomedical research: 
informed consent, confidentiality, quality
issues, ownership, return of benefits. A professional 
perspective – B. Godard et al (2003)
Public Access to Genome-Wide Data: Five Views on 
Balancing Research with Privacy and Protection –P3G 
Consortium Church et al (2009)
Resolving Individuals Contributing Trace Amounts of DNA 
to Highly Complex Mixtures Using High-Density SNP 
Genotyping Microarrays, N. Holmer (2008)
PACITA - Expert Working Group Report, Expert Paper and a 
Policy Brief (2014) 
Special Report
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Text: Dirk Stemerding and André Krom
An important future challenge facing healthcare systems 
in Europe is how to deal with data and technologies 
provided by advanced genetic research. DNA sequencing 
technologies are rapidly becoming cheaper and faster. 
Experts expect that this will ultimately give us the tools 
to understand individual genomes and to accurately 
predict their consequences, thus allowing for detailed risk 
profiling of individuals as the basis for targeted medical 
interventions. The promise is more effective health 
care practices that are more personalized, predictive, 
preventive, and consumer-driven. 
However, experts also see a clear threat that premature 
technology and market driven applications of DNA 
sequencing will inundate physicians and patients with 
meaningless or uninterpretable data. There is a wide gap 
between our ability to generate ‘more data for less money’ 
and our ability to understand them or validate their clinical 
utility. Indeed, political intervention is needed to guarantee 
that the use of genomic technologies in public health 
services does not lead to detrimental consequences. 
Step-by-step approach needed
These promises and concerns warrant a careful, step-
by-step approach to the development and diffusion 
of genome-based information and technologies. The 
challenge for policy makers at the European and national 
level is what a step-by-step approach might involve in their 
own countries. As the Future Panel process made clear, 
we should not think of the future in terms of Public Health 
Genomics as a ‘road map’ taking us in one particular 
direction. We should rather carefully look at the variety of 
ways in which any single new development could affect the 
health care landscape in the future. Determining acceptable 
ways in which health care practices could be improved 
by genomic information and technologies thus requires 
political and societal debate.
One important issue is the increasing quantity of data 
travelling between research and patient care whereby data 
collected for medical purposes are shared for research 
purposes and statistical analysis. Most variation in our DNA 
has not yet been investigated and we cannot yet assign 
potential consequences to this variation for individual 
health and disease. In order to establish such relationships, 
it will be necessary to combine clinical and genomic data 
from large numbers of individuals and to collect these 
data in an extended network of ‘biobanks ‘. This raises 
challenging questions about data security and privacy, as 
becomes clear from the Special Report in this VOLTA issue.
DNA sequencing technologies are also being introduced 
already in a clinical context, especially for diagnosis in 
children born with congenital disabilities and/or mental 
retardation, and for prenatal diagnosis of abnormalities 
observed during ultrasound. As available DNA-sequencing 
technologies are rapidly becoming cheaper and faster, it 
may become more and more routine to sequence genes 
or even whole genomes of individuals to screen them for 
particular medical conditions or health risks. Possibilities 
for whole-genome sequencing in widely established 
programs for reproductive and newborn screening are 
currently intensively debated by scientists and clinicians 
and may raise in the near future difficult questions of what 
and when to screen for.
Newborn screening
An important development raising debates about 
possibilities of genome-wide screening is the introduction 
of non-invasive prenatal testing (NIPT) as a replacement 
for established forms of prenatal screening for Down 
Syndrome. NIPT is based on the analysis of foetal DNA 
isolated from the maternal blood and can be used as a 
screening tool for Down Syndrome and other chromosomal 
abnormalities. However, as soon as NIPT becomes widely 
available in a setting of routinely offered prenatal screening, 
it may also create opportunities for the introduction of 
more genome-wide forms of screening. In this context, new 
questions will arise about what information to offer in the 
context of reproductive choice, questions that may become 
especially urgent as a result of commercial initiatives in 
offering NIPT.
Established programs for newborn screening (NBS) are 
another context in which genome-wide screening might 
be considered. NBS programs in Europe currently aim to 
identify 1 to 30 treatable conditions. Taking into account 
current developments in DNA sequencing, targeted 
genome-wide screening for a panel of well-chosen 
diseases could be envisaged based on the criteria used 
or suggested today to develop a screening program. If 
indeed a switch would be made to genome-wide screening 
in NBS programs, a more far-reaching possibility would be 
to keep the whole genome sequence of the newborn for 
future use. The sequence information could be stored in the 
clinical record to be available for analysis when dealing with 
specific individual health issues or risks later in life.
Obviously these new possibilities raise challenging 
questions, both about the scope of genome-wide screening 
options offered to individuals, and about the importance 
and meaning of informed consent as a fundamental patient 
right. How to avoid that genome-wide screening becomes 
an intractable burden to informed decision-making? And to 
what extent do parents have the right to make far-reaching 
decisions about full genome analysis for their children 
without knowing the possible benefits of such an analysis 
at the time taken?
Policymakers will increasingly have to face such questions 
in the near future. The aim of the PACITA Future Panel 
project has been to enable parliamentarians, policy 
makers, health care providers and other stakeholders 
to make informed and country-specific decisions about 
the introduction of genome-based information and 
technologies (GBIT) into a variety of health care settings. 
The project yielded suggestions for a step-by-step 
approach to the introduction of GBIT in health care on a 
European level. A challenge for national governments is 
now to determine what a step by step approach to the 
introduction of GBIT in health care will require in their 
country.
PACITA Future Panel: Parliamentarians in Europe 
discuss genomics in public health care
Special Report
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In January 2014, a Future Panel of parliamentarians from Europe came together for a policy hearing in the Portuguese 
Parliament to discuss issues and options for the future of ‘public health genomics’. The event in Lisbon concluded one 
of the three PACITA demonstration projects. The project was a collaborative experience involving partners from The 
Netherlands, Germany, Lithuania and Portugal.
At the start of the project in November 2012, parliamentarians from the Future Panel identified major policy questions 
relating to the future of public health genomics. These were the starting point for an expert consultation process resulting 
in four Expert Working Group Reports focusing on different themes. On the basis of these reports an Expert Paper was 
produced focusing on policy issues raised by developments in public health genomics. Finally, policy options for dealing 
with these issues have been described in an extended Policy Brief that served as an agenda for the Policy Hearing in 
Lisbon.
Read more
Find all the reports, interviews, presentations, photographs,  
and the policy brief on Public Health Genomics on www.pacitaproject.eu
Future Panel
PACITA policy hearing experts & organizers: Iñaki Gutiérrez-Ibarluzea (Spain), Klaas 
Dolsma, André Krom and Dirk Stemerding (the Netherlands), Mara Almeida (Portugal).
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Proceedings from the PACITA 
2013 Conference in Prague
Mankind has never before 
dealt with such an enormous 
quantity and intensity of life 
changing technologies. The 
European Technology Assessment 
Conference that took place in 
Prague in March 2013 shed a light 
on many of these grand challenges. 
In its 22 sessions, it became clear 
there should be a specific form 
of TA; one which is open to the 
general public. In the first keynote 
speech Wiebe Bijker spoke of 
how we must make TA about 
democracy: the state must return 
from its neoliberal retreat and 
become an advocate of democratic 
governance. Stefan Boeschen 
calls TA an important building 
block of the democratic culture. 
Rut Bízková mentioned smart 
infrastructure as a prerequisite 
for sustainable competitiveness.  
But symbols of trust and ethical 
values are essential for TA. The 
diversity of languages and lack of 
unified politics are just the most 
visible obstacles: cross-European 
TA must address tension that can 
arise between different national 
and regional structures. It’s a 
need that is clearly manifested 
in all the contributions to these 
Proceedings, which will be 
available online in May 2014.  
www.pacitaproject.eu
Journal of Responsible 
Innovation
The new Journal of Responsible 
Innovation (JRI) offers humanists, 
social scientists, policy analysts 
and legal scholars, and natural 
scientists and engineers an 
opportunity to articulate, 
strengthen, and critique the 
relations among approaches to 
responsible innovation, thus giving 
further shape to a newly emerging 
community of research and 
practice. These approaches include 
ethics, technology assessment, 
governance, sustainability, socio-
technical integration, and others. 
JRI intends responsible innovation 
to be inclusive of such terms as 
responsible development and 
sustainable development, and the 
journal invites comparisons and 
contrasts among such concepts. 
JRI is open to alternative styles 
or genres of writing beyond 
the traditional research paper 
or report, including creative or 
narrative nonfiction, dialogue, and 
first-person accounts, provided 
that scholarly completeness and 




Smart phones, social media, 
cameras and biosensors mean 
more and more information about 
our bodies and behavior are 
becoming digitally available. Our 
lives are increasingly becoming 
intertwined with technology. 
But allowing technology into 
our private worlds collides 
with the most crucial issues 
of our humanity. It leads to a 
struggle for our intimacy. The 
Rathenau Instituut has called 
this the intimate-technological 
revolution. This report highlights 
how the application of human-
like technology, such as digital 
coaches, realistic avatars and 
robots are blurring the boundaries 
between humans and technology 
even further. Important ethical 
questions touch on the basic rights 
and dignity of people, their right 
to privacy, physical and mental 
integrity, the right to live in a safe 
environment, the right to have 
private property, and freedom 
of thought and conscience. 
Governments and private 
companies want our data in order 
to create profiles and influence 
our behavior. Technologies with 
human features, such as digital 
coaches, realistic avatars and 
robots yield the ability to influence 
human behaviour. How can we 
avoid being manipulated?  Which 
social tasks can we humanely 
delegate to machines, and which 
not? What autonomy do we wish 
to keep?
Intimate Technology The 
Battle for our Body and 
Behaviour. 
Rinie van Est, with the assistance 
of Virgil Rerimassie, Ira van 
Keulen & Gaston Dorren. 









VolTA previews the proceedings of the conference on Grand Challenges, 
a new journal covering responsible innovation and a report from the 











Technology Assessment has a large toolbox of 
methods involving a range of different actors. The 
CIPAST-project (Citizen Participation in Science and 
Technology), which ended in 2008, described many 
of them, particularly those involving citizens. The 
focus group was one of the methods presented.  
A focus group is a structured group interview, first 
used in the United States in the 1980s by sociologist 
Robert Merton. A group is composed of participants 
who have specific knowledge or experience 
of the topic at hand. This could be ‘teenagers 
who use smart phones’, or ‘parents of 
children with asthma’ or ‘workers at a car 
factory’.  
The scope of a focus group is limited and 
defined in advance by the researcher. They 
follow a semi-structured interview format, 
where the researcher asks prompting 
questions. However, it is important that the 
discussions are open, so that the participants 
can share their experiences and comment on 
each other’s views. This is the strength of 
this method:  the discussions and interaction 
between the participants produces more 
information than the participants would 
provide one by one. Another advantage 
of the focus group is that it allows the 
researcher to document the processes 
whereby group meanings are shaped, elaborated and 
applied, by letting the participants discuss and share 
with each other. As the participants are selected 
based on their own experiences, the focus group is 
an effective method for providing information on 
attitudes, values and societal norms – for example 
what teenagers think about privacy issues related to 
their own smart phone use. 
Several institutions in the field of technology 
assessment have used focus groups in their projects. 
In 2010 the Norwegian Board of Technology (NBT)’s 
Patient 2.0 project was trying to ascertain what 
people with chronic illnesses thought about online 
health services. Recruitment for the group was done 
in cooperation with some of the largest patient 
organizations in Norway with a total of 21 patients 
participating. 
“The focus groups provided important insights on 
what kind of services the patients needed, what they 
expected from the care services and their experiences 
with already implemented online solutions”, 
according to NBT project manager Jon Fixdal.  
Drawing on their own experiences with the health 
care system, patients wanted the possibility to add 
information about their daily condition into their 
patient journal, so that it could be discussed with 
their doctor later. Another recommendation was to 
establish an online health portal, for finding quality 
assured health information. 
Fixdal highlights another aspect of the focus 
groups – the fact that it is well suited for multi-
method projects. In Patient 2.0, focus groups were 
held together with an expert group. Both methods 
proved valuable and the recommendations produced 
for the decision-makers were listened to. Getting 
expert opinions from research and industry, but also 
user experience from patients, was welcomed by 
parliamentarians. 
The Method – New and old Technology Assessment methods
Focus groups
 
Policy makers need to know what people think about certain topics 
and why. This important information can be revealed through open 





'Teenagers who use 
smart phones' is a topic 
suitable for a focus group 
Read More?
CIPAST – Citizen participation in science and technology 
(www.cipast.org/cipast.php?section=10111) 
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Attila Havas on strategic thinking:
The benefits of foresight





“There are even stronger needs for strategic 
thinking in Central and Eastern European (CEE) 
countries than in the advanced ones, given their 
specific challenges”, claims Attila Havas from the 
Hungarian Academy of Sciences. “In particular, their 
fundamental political and socio-economic transition 
processes, as well as major changes in their external 
environment. Yet, long-term thinking is discredited 
across the region for historical reasons. Although the 
CEE countries would clearly benefit from conducting 
foresight programmes, policy-makers do not rely on 
modern decision-preparatory tools to a sufficient 
extent.” 
Obstacles to foresight
There are various obstacles. “To start with a very 
simple one, in several countries the history of the 
current legal entity goes back just over twenty years. 
Therefore a foresight project with a time horizon 
of 20-25 years sounds shocking.” Although CEE 
countries are faced with a compelling need for 
fundamental changes in their health care, education, 
and pension systems, among others, decision-makers 
tend to focus on fire-fighting rather than thinking 
about long-term issues in a participatory way. 
In other words, short and long-term issues are 
competing for problem-solving intellectual 
resources, the attention of politicians and policy-
makers who decide on the allocation of funds, and 
the attention of opinion-leaders who can set the 
agenda. These intellectual and financial resources 
are always limited, thus choices have to be made. 
A well-designed foresight process can help identify 
priorities, in terms of striking a balance between 
short- and long-term issues. It could also raise the 
profile of science, technology and innovation (STI) 
on the political agenda. CEE politicians tend to look 
at STI as a burden on the budget, and not as a source 
of solutions. When public expenditures need to be 
cut, the first victim would be the budget for STI, 
education and culture. Changing that attitude would 
be crucial.
Changing the historical mindset
In some European democracies, the role of 
government is shifting from being a central 
steering entity to that of a moderator of collective 
decision-making processes with the conviction that 
stakeholders need to be involved for government 
policies to be more effective. However, in CEE 
countries there seems to be distrust towards 
decentralised decision-making.
“It is probably due to the history we shared for 
centuries where consensus was not the main method 
of making decisions”, suggests Havas. “CEE history 
is laden with severe conflicts, including wars and 
civil wars and empires occupied large parts of 
our region for long times. Simply because of this 
historical legacy, the mindset of people is not geared 
towards future-oriented thinking and consensual 
decision-making.”
Foresight is always a learning process for those 
involved. It is not only the ‘products’ – i.e. the 
different documents, final reports, and policy 
recommendations – that are important but also 
the ‘process’ itself, namely disseminating a new, 
participatory, transparent, future-oriented decision-
making culture; intensified networking, co-operation 
and institution-building activities. In other words, 
a foresight programme can contribute to the 
strengthening of the national system of innovation 
in two ways: through reports, recommendations as 
well as via facilitating the communication and co-
operation among various professional communities. 
The power of informal communication
CEE policy-makers should be inspired to rely more 
on modern decision preparatory tools and a mix of 
methods would be needed to foster understanding 
the relevance of these tools.  Tailored workshops to 
stimulate interactive learning would be particularly 
effective (not the one-way, codified knowledge flow 
of traditional training seminars). Writing lengthy and 
elaborate reports will not be as successful as direct, 
face-to-face communication between policy-makers. 
Networking, personal communication, the transfer of 
tacit knowledge is crucial, even if it is not measured 
directly. “I think the close links among the members 
of the European foresight, TA, and evaluation 
community, along with the collegial atmosphere, 
is really a strength. I have only met colleagues who 
were ready to help, share their experience, and reflect 
critically as well.”
Havas has recently been involved with the 
preparation of the smart specialisation strategies 
for 2014-2020. (Smart specialisation is a new 
policy concept designed to promote the efficient and 
effective use of the EU Structural Funds.) Foresight 
methodologies have not yet been used in Hungary to 
that end. “I can recall a few cases when foresight is 
used to prepare the new planning documents. One 
is Lithuania. They have just completed a national 
‘Because of the historical legacy, 
the mind set of people is not geared 
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Attila Havas is a Senior Research Fellow at the Institute 
of Economics, Centre for Regional and Economic Studies 
Hungarian Academy of Sciences, and regional editor of 
International Journal of Foresight and Innovation Policy. 
His academic interests are in evolutionary economics of 
innovation, systems of innovation, innovation policy, and 
technology foresight. In 1997-2001 he was Programme 
Director of TEP, the Hungarian Technology Foresight 




foresight programme on their research and higher 
education system and are using the results to prepare 
the smart specialisation strategy for 2014-2020. 
Portugal is also planning a foresight-type programme 
to underpin their smart specialisation strategy.”
About future recommendations for the region 
Attila Havas is very clear: There should always be 
a very strong national commitment. It is important 
to engage in international co-operation, but it is 
always crucial to have commitment from domestic 
stakeholders. “If at some point there was a pressure 
on the EU to conduct or fund TA activities in this or 
that country, I don’t think that would be a good idea. 
Co-financing might be helpful, especially in terms 
of covering the costs of foreign experts, but there 
should always be a strong domestic commitment, in 
terms of the financial and human resources devoted 
to TA. Without that there is no hope that these tools 
might become part of the decision-making process in 
this region.” 
‘A well-designed foresight process 
can help identify priorities, in terms 
of striking a balance between short- 
and long-term issues.’
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How can we overcome the challenges related 
to health and wellbeing posed by demographic 
changes all over Europe? How can we provide safe 
societies for citizens? Or food security, sustainable 
agriculture, smart transport, clean energy? These are 
just some of the societal challenges in Europe that 
Horizon2020 will be addressing in the coming years. 
Since 1984, the European Union has organized 
its research and innovation efforts in Framework 
Programmes. It has sought cooperation between 
different types of actors and supported the entire 
process from basic science to innovation through to 
implementation in society. Lars Klüver, Director of 
the Danish Board of Technology Foundation, has 
been involved in EU-funded projects for many years 
and has seen this trend of involvement evolve: “The 
focus has slowly moved from new technology to 
finding solutions to societal challenges. This shift 
started with the Fifth Framework Programme, but 
has got real momentum in Horizon2020.”
“Simultaneously we see increased interest for 
engaging different actors in the research. It started 
with small and medium sized enterprises and 
civil society organizations in the last Framework 
Programmes but in Horizon 2020 the involvement 
goes further,” reports Klüver. “Several calls 
encourage the direct involvement of citizens, users 
and stakeholders. Seeing how societal challenges 
demand a broad knowledge base and support from 
citizens, this involvement seems only natural”.
This is not unfamiliar territory for technology 
assessment professionals. Through three example 
projects - public health genomics, the future of 
ageing, and sustainable consumption - the PACITA 
project has started looking at the grand challenges 
of Europe and the example projects have shown the 
importance of involvement of different actors. With 
experts, stakeholders and citizens playing a role, 
technology assessment can be one way of dealing 
with these challenges. There are many possibilities 
for TA-projects to get funding through Horizon2020, 
believes Klüver, especially for those institutions that 
involve citizens and civil society in their work.
PACITA has a long-term goal of strengthening the 
basis for technology assessment (TA) in Europe, both 
on a structural and methodological basis. Klüver is 
convinced that the Commission sees the value in a 
project like PACITA, and recognizes that it takes 
time to implement this work into ‘real life’. “We do 
hope there will be opportunities to continue this 
work in one form or another through Horizon2020. 
Looking at the intentions of Horizon 2020, one 
could say that a natural development would be to 
strengthen the field of technology assessment all over 
Europe. Technology Assessment has always strived to 
identify solutions and maneuvers that are robust for 
society – both technologically and politically.”  
Masterclass – Horizon2020 
Big Society  
The EU’s latest Framework Programme for research and innovation 
kicked off in 2014 with a new name and it’s biggest ever budget. Over 
the next seven years, nearly 80 billion euros (plus further private 
investment) will be spent on collaborative projects across Europe. 
‘We need a new vision for 
European research and innovation 
in a dramatically changed 
economic environment.’ Máire 









The latest information on projects and partners. 
http://ec.europa.eu/programmes/horizon2020/  
The European Commission’s home page on the Framework 
with links to other Commission departments. 
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State of mind? 
Right now, I'm working on several 
serial projects for television. We 
are still awaiting a decision for a 
third series of Real Humans.
 Biggest success? 
A series called Tusenbröder 
(Brothers in crime) was a huge 
success in Sweden, so was also a 
comedy series called Pistvakt. But 
the greatest international success 
has been Real Humans. 
How did you get where you are? 
I've had my share of luck, 
combined with hard work and 
stubbornness. 
Failures? 
Oh yes, some stuff will fly and 
some will not. That's the way it 
works. You have to be an explorer 
and in being that, you will always 
take a wrong path every now and 
then. You can learn a lot more 
from failures, to be honest. But 
with no successes you won’t keep 
that privilege to fail.
Dreams? 
I seldom remember my nightly 
dreams. I can daydream 
uncontrolled sometimes about a 
relaxed life with no ties or worries 
on a tropical island far far away - 
just like the majority of people in 
the north of Europe. You know, 
it's my job to dream in a way, and 
I write them down for a living.
What will it take? 
More hard work I'm afraid. 
Biggest fear? 
To be struck by a deadly disease or 
that something bad will happen to 
those I love and care about. 
What inspires you? 
Life and the human struggle. 
Could you share your plans for the 
future?
 Right now I don't know what's 
going to be my next project to 
be realised. I'm developing a few 
pieces and I'm also engaged in the 
development of other projects in 
Matador Film. Of course we are 
hoping for a third series of Real 
Humans. 
What would you change?
Right now, nothing of the stuff 
that really matters. 
See More? 
The Swedish sci-fi drama series 
Äkta människor (Real Humans) 
premiered on 22 January 2012 
on SVT1 and has been sold to 
around 50 countries around the 
world. It raises key ethical issues 
related to the encroachment of 
technology in society, according to 
Lundström: “How can we sustain 
humanity and tolerance despite 
these changes? What is a ‘human 
being’?” His favourite character 
is re-programmed (with a free 
will) hubot Mimi: “She is the 
main conflict-zone in the series, 








Picture from the TV 
series: Johan Paulin
Highlight 
Real Humans  
In the drama series Real Humans written by Lars Lundströ, humanoid 
robots are servants, workers, company for the lonely and even sex 
partners. His inspiration? “Technology has slowly taken over our lives, 
not only in the practical sense but also socially and emotionally”. 
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Feature – Global warming
Will we need geoengineering 
to save the world? 
Despite numerous international climate conferences, agreements, 
protocols and treaties, we are not managing to reduce global carbon 
emissions or stall climate change. Is geoengineering the answer?
Imagine looking up in the sky. There, many miles 
above your head, you see what looks like a gigantic 
mirror. It is actually an enormous solar shield 
launched to reflect sunlight and reduce the amount 
of solar energy heating the earth. It is part of a last 
ditch effort to save us from total environmental 
catastrophe. It is geoengineering. 
Geoengineering is an umbrella term for large-scale 
interventions to counteract anthropogenic (human 
caused) climate change. These efforts can be divided 
into two broad categories: those aimed at carbon 
dioxide capture from the atmosphere and subsequent 
long term storage, and those aimed at counteracting 
the effects of global warming through solar radiation 
management (SRM). 
The main difference between these two types is that 
the first aims to reduce the concentration of CO2 
in the atmosphere, thus making it more likely that 
our emissions not will exceed 350 ppm (parts per 
million), often quoted as the ‘target' ratio for carbon 
dioxide molecules in order to prevent significant 
climate change. Those aimed at limiting the amount 
of solar energy on the other hand, are aimed at 
reducing the direct heating of the globe. They do not 
address the problem of increased amounts of carbon 
gasses in the atmosphere. 
Space reflectors are just one of a wide range of 
geoengineering proposals. For CO2 reduction, 
suggestions include Ocean fertilization or 





Will geo engineering 
pave the way for 




the growth of certain types of plankton. These small 
organisms feed on CO2 and live near the surface 
of water where there is sufficient light to support 
photosynthesis. Afforestation on a very large scale, 
would enable the removal of CO2 until the trees were 
cut down or decomposed. CO2-capture from the air 
would involve building huge processing towers that 
suck in air and using sodium hydroxide, remove the 
CO2 as the air passes through the tower. 
Solar radiation projects include stratospheric 
aerosols: dispersed into the stratosphere, these 
aerosols are designed to reflect sunlight and increase 
cloud condensation. Sun reflectors in deserts would 
involve large desert surfaces being covered with sun-
reflecting sheets. The basic idea is the same as for 
space reflectors - to reflect sunlight and thereby slow 
down the heating of the globe. 
Ongoing afforestation can be considered as an 
example of existing geoengineering but is currently 
on a small scale. If geoengineering is to play a key 
role in the future, it needs to be scaled up raising 
numerous questions related to technological 
readiness, costs, safety and possible side effects. 
Some geoengineering technologies are ‘readier’ than 
others. Injecting sulfur into the stratosphere will 
probably not be technologically difficult neither will 
afforestation. But building reflectors large enough to 
reflect significant amounts of solar energy presents 
an enormous technological challenge. Air capture 
with CO2 removal? Will we be able to store the 
necessary amounts of CO2?
Costs and side effects
The costs and financing of geoengineering projects 
will obviously be a major issue but also the 
side effects of intervention. For example, ocean 
fertilization could lead to nutrient depletion. As 
the plankton grow, they will not only eat the CO2, 
as intended, but also other nutrients that other 
organisms eat. Another example of side effects is 
that spreading aerosols into the atmosphere is can 
reduce rainfall in the tropics.  The particles that are 
meant to absorb heat from the sun may also absorb 
some of the heat energy that comes from the surface 
of the planet. This heat plays an important role in 
the production of tropical rainfall, with a danger 
of causing significant harm to some of the most 
important ecosystems of the globe. The key point is 
that geoengineering will come at significant cost, and 
side effects will be difficult – if not impossible – to 
predict. 
We already know what needs to be done to mitigate 
climate change. Enormous, costly and high risk 
projects need not be part of the solution.  On the 
other hand, you do not have to be a full-blown 
pessimist to believe that the need for large-scale 
geoengineering may arise. Despite numerous climate 
protocols, international climate agreements, climate 
conferences and climate treaties, global carbon 
emissions are not falling. We must believe (and 
hope) that any geoengineering activities will only be 
done on the basis of numerous and very extensive 
analyses. These should involve a very broad variety 
of institutions (research, civil society, TA-institutions 
etc.) and cover issues ranging from technological 
possibilities, possible consequences and economics, 
to risks, safety and ethics. It will most probably 
require broad international cooperation. 
TA institutions could play a particularly important 
role in fostering public debate. Several TA intuitions 
are highly competent in designing and facilitating 
participatory processes that provide opportunities 
for affected citizens to have their say. Geoengineering 
raises profound questions about whether we should 
risk tampering with nature, which risks we are 
willing to take, and how the benefits should be 
weighed against possible negative consequences. 
These will essentially be normative questions of 
great importance to future life on earth. They should 
not be left to any single group in society, whether 
technologists, scientists, lawyers or policy makers. 
The choices should be based on broad societal debate 
in which ordinary citizens should be included. 
‘If geoengineering is to play a key 
role in the future, it needs to be 
scaled up raising numerous questions 
related to technological readiness, 
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Is Geoengineering a Case for TA?
Yes. With a mission of providing advice to policy makers on 
pressing policy issues, TA can foster critical reflection on 
which of these (if any) technologies should be developed 
and how the benefits should be weighed against possible 
side effects. And not least, TA can stimulate public debate 
as a means for the democratization about technological 
choices.
Several TA institutes have done studies on geoengineering:
In 2009, the UK Parliamentary Office on Science 
and Technology (POST) published Geo-Engineering 
Research, which summarized the arguments related 
to research funding. It suggested: “A relatively modest 
research programme, with a UK contribution of £10-20M 
could advance relevant knowledge significantly.” Climate 
engineering research programmes are currently ongoing at 
several universities in the UK.
The Rathenau Instituut is conducting research into 
various forms of climate engineering and in 2013 published 
a policy brief entitled Climate engineering: hype, hope or 
despair? One of their recommendations was to put Carbon 
Dioxide Removal technology on the agenda of the climate 
negotiations in 2015 in order to include regulations in the 
Climate Agreement. 
The Office of Technology Assessment at the German 
Bundestag Büro für Technikfolgen-Abschätzung beim 
Deutschen Bundestag (TAB) is currently working on a 
comprehensive overview (2011-2014) of the current state 
of knowledge with regard to technological and natural 
scientific aspects of the different geoengineering concepts 
proposed and exploring the facets of these concepts in 
terms of (international) law, ethics, socio-economics and 
politics. “Science has only just started to deal with these 
and other questions so that there is still a considerable lack 
of knowledge.”
Read More? 





GAO (Government Accountability Office, USA) -  
www.gao.gov/products/GAO-11-71 
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Speakers' Corner – Europe on Science, Technology and Society
Energy 2030 
The policy of the future  
 
Declaring the  European Commission’s 2030 framework for climate and 
energy policies ‘short-sighted and unambitious’, the European Parliament 
called for tougher energy targets and an amendment making the renewables 
target nationally binding. What do members of parliament think?
We need three binding objectives
"If we want to reduce our energy imports we have 
to produce more in Europe. If we have a broad 
energy mix with greater energy efficiency, this is 
the best option to reduce greenhouse gas emissions, 
to encourage new technologies and innovation, 
create jobs, and change our economies into greener 
economies. This is why we need three binding 
objectives. The European Commission proposal is an 
acceptable work base but needs to be strengthened. 
It is disappointing that we cannot yet confirm the 
benefits of energy efficiency. Energy efficiency alone 
would enable us to reduce our energy bills, our 
dependence on countries producing oil and gas and 
our energy trade balance and to create thousands 
of jobs in Europe, not to mention improving our 
protection of our environment and our climate."
Anne Delvaux (Belgium) European People’s Party, 
co-rapporteur for the environment committee 
www.anne-delvaux.be
Targets still fall short
"Apart from the 40% greenhouse gas reduction goal, 
these targets still fall short of what is needed, if only 
to be credible to our global partners. I regret that 
the Commission didn’t propose a binding target on 
energy efficiency. We believe the opposite: in the 
interest of our industry and our jobs, we must have 
a firm political commitment to emission reduction, 
renewables and energy efficiency.”
Matthias Groote (Germany),  Group of the 
Progressive Alliance of Socialists and Democrats, 
chairman of the environment committee 
www.matthias-groote.de
Binding objectives are not flexible
"This result is not satisfactory. We are promising 
ourselves, Europeans and European industry, 
that this new climate policy would be realistic, 
flexible and cost- efficient[...]Binding objectives on 
renewables and energy efficiency is not a flexible 
arrangement. We know well that member states 
and individual sectors have different capacities. The 
European Commission hasn't understood the current 
impact and influence of the climate policy on the 
European economy. Increasing the binding target for 
energy from renewables to 27% does not take into 
account the electricity price impact of this policy. 
Raising the CO2 reduction target to 40% is at best 
premature."
Konrad Szymański (Poland), European Conservatives 
and Reformists group, co-rapporteur from the 




“These numbers are madness. How many times 
will they change by 2030? Our industry needs a 
stable and foreseeable framework to boost long-
term investments. Instead, the parliament proposes 
unrealistic numbers! […] We should have focused on 
one objective of reducing greenhouse gas emissions 
by 2030. Member states should have the necessary 
freedom and flexibility to decide their energy mix.”
Françoise Grossetête, (France) European People’s 
Party 
www.francoise-grossetete.eu
Text: 
Katalin Fodor
Read More? 
www.euractiv.com/energy
http://ec.europa.eu/energy
www.europarl.europa.eu/oeil
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